BBIO Covered Call Strategy
BBIO (BridgeBio Pharma, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1).
BBIO (BridgeBio Pharma, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $16.42B, a beta of 0.98 versus the broader market, a 52-week range of 46.81-93.415, average daily share volume of 3.1M, a public-listing history dating back to 2019, approximately 837 full-time employees. These structural characteristics shape how BBIO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.98 places BBIO roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a covered call on BBIO?
A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.
BBIO snapshot
As of August 14, 2026, spot at $79.78, ATM IV 43.70%, IV rank 7.46%, expected move 12.53%. The covered call on BBIO below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this covered call structure on BBIO specifically: BBIO IV at 43.70% is on the cheap side of its 1-year range, which means a premium-selling BBIO covered call collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 12.53% (roughly $10.00 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated BBIO expiries trade a higher absolute premium for lower per-day decay. Position sizing on BBIO should anchor to the underlying notional of $79.78 per share and to the trader's directional view on BBIO stock.
BBIO covered call setup
The BBIO covered call below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With BBIO at $79.78 on that close, the first option leg uses a $85.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed BBIO chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 BBIO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $79.78 | long |
| Sell 1 | Call | $85.00 | $2.48 |
BBIO covered call risk and reward
- Net Premium / Debit
- -$7,730.50
- Max Profit (per contract)
- $769.50
- Max Loss (per contract)
- -$7,729.50
- Breakeven(s)
- $77.30
- Risk / Reward Ratio
- 0.100
Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.
BBIO covered call payoff curve
Modeled P&L at expiration across a range of underlying prices for the covered call on BBIO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$7,729.50 |
| $17.65 | -77.9% | -$5,965.63 |
| $35.29 | -55.8% | -$4,201.76 |
| $52.93 | -33.7% | -$2,437.89 |
| $70.56 | -11.6% | -$674.02 |
| $88.20 | +10.6% | +$769.50 |
| $105.84 | +32.7% | +$769.50 |
| $123.48 | +54.8% | +$769.50 |
| $141.12 | +76.9% | +$769.50 |
| $158.76 | +99.0% | +$769.50 |
When traders use covered call on BBIO
Covered calls on BBIO are an income strategy run on existing BBIO stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
BBIO thesis for this covered call
The market-implied 1-standard-deviation range for BBIO extends from approximately $69.78 on the downside to $89.78 on the upside. A BBIO covered call collects premium on an existing long BBIO position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether BBIO will breach that level within the expiration window. Current BBIO IV rank near 7.46% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on BBIO at 43.70%. As a Healthcare name, BBIO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to BBIO-specific events.
BBIO covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. BBIO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move BBIO alongside the broader basket even when BBIO-specific fundamentals are unchanged. Short-premium structures like a covered call on BBIO carry tail risk when realized volatility exceeds the implied move; review historical BBIO earnings reactions and macro stress periods before sizing. Always rebuild the position from current BBIO chain quotes before placing a trade.
Frequently asked questions
- What is a covered call on BBIO?
- A covered call on BBIO is the covered call strategy applied to BBIO (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With BBIO stock at $79.78 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed BBIO chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are BBIO covered call max profit and max loss calculated?
- Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the BBIO covered call priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 43.70%), the computed maximum profit is $769.50 per contract and the computed maximum loss is -$7,729.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a BBIO covered call?
- The breakeven for the BBIO covered call priced on this page is roughly $77.30 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The BBIO market-implied 1-standard-deviation expected move in the same options snapshot is approximately 12.53%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a covered call on BBIO?
- Covered calls on BBIO are an income strategy run on existing BBIO stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
- How does current BBIO implied volatility affect this covered call?
- BBIO ATM IV is at 43.70% with IV rank near 7.46%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.